MILabs Broadband Photon Tomography nominated for Innovation of the Year - WMIC 2018

MILabs is pleased to announce that its new Broadband Photon Tomography technique has been nominated for the Innovation of the Year 2018 award by the World Molecular Imaging Society (WMIS) board of trustees.

September 4, Seattle, USA and Utrecht, the Netherlands

MILabs is pleased to announce that its new Broadband Photon Tomography technique has been nominated for the Innovation of the Year 2018 award by the World Molecular Imaging Society (WMIS) board of trustees.

Broadband Photon Tomography as implemented on MILabs’ new VECTor6 platform, dramatically expands the versatility and performance of preclinical imaging systems. For the first time, it is possible to perform nuclear and optical molecular imaging techniques on a single platform, enhanced by diagnostic and molecular X-ray CT. PET and SPECT images can now be acquired at unprecedented high resolutions, even for PET isotopes that exhibit positron ranges of several mm’s such as 82Rb and 124I, while Optical Images can be visualized in three-dimensions. Moreover, multiple PET isotopes, as well as co-injected PET/SPECT tracers, can be imaged simultaneously and 3D OPT/CT images obtained with single acquisitions.

By imaging a photon energy range from 1eV to 1 MeV. The unique capabilities of Broadband Photon Tomography are expected to extend the application reach of in-vivo animal imaging far beyond the capabilities of current preclinical PET, SPECT, Optical and CT systems.

About MILabs B.V.

The company has a history of providing a continuum of innovations to expand the applications of its multimodality imaging solutions used for the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. With its 6th generation preclinical VECTor platform, MILabs has succeeded at integrating six imaging modalities in a single system to deliver cost-effective high-definition molecular, functional and anatomical imagers to researchers worldwide. For more information, visit www.milabs.com or contact MILabs at info@milabs.com

MORE ON THIS TOPIC